BFM
MTNB icon

Boothbay Fund Management’s Matinas BioPharma MTNB Stock Holding History

Boothbay Fund Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200
Closed -$23K – 979
2019
Q4 		$23K Buy
+200
New +$11.6K ﹤0.01% 819
2018
Q4 		– Sell
-850
Closed -$39K – 798
2018
Q3 		$39K Buy
+850
New +$18.3K ﹤0.01% 750

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boothbay Fund Management's MTNB Position: Q1 2020 in Review

Boothbay Fund Management sold out of Matinas BioPharma (MTNB) in Q1 2020, closing a stake of 200 shares — an estimated $23K sold.

Boothbay Fund Management first reported a position in MTNB in Q3 2018 and held it in 2 quarters. The position peaked at $39K in Q3 2018. 68 funds tracked by Wall St. Rank hold MTNB as of Q1 2020.

  • Boothbay Fund Management reported no remaining Matinas BioPharma position as of Q1 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 200 Matinas BioPharma shares in Q1 2020, an estimated $23K.
  • Boothbay Fund Management first reported a position in Matinas BioPharma in Q3 2018 and held it in 2 quarters.
  • Boothbay Fund Management's Matinas BioPharma position peaked at $39K in Q3 2018.
  • 68 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2020.

Based on Boothbay Fund Management's 13F filing for Q1 2020, filed 15 May 2020.